Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT8L6P)

Drug Name

BMS-817399 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 1 (CCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CCX-354	DMSHV9C	Autoimmune diabetes	5A10	Phase 2	[3]
AVE1701	DMJY35M	Rheumatoid arthritis	FA20	Phase 1	[4]
AZD4818	DM3VFKM	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[5]
MLN3897	DMRA3EZ	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[4]
COSALANE	DMO3486	N. A.	N. A.	Terminated	[6]
A-987306	DMU34BK	Discovery agent	N.A.	Investigative	[7]
BX 471	DM5CGXB	Discovery agent	N.A.	Investigative	[8]
Cosalane derivative	DMSFXJ8	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 1 (CCR1)	TTC24WT	CCR1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01404585) Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis. U.S. National Institutes of Health.
2	Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64.
3	Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.
4	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
5	Clinical pipeline report, company report or official report of AstraZeneca (2009).
6	Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62.
7	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
8	Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8.